Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

被引：24

作者：

Pizzuti, Laura ^{[1
]}

Giordano, Antonio ^{[2
]}

Michelotti, Andrea ^{[3
]}

Mazzotta, Marco ^{[4
]}

Natoli, Clara ^{[5
]}

Gamucci, Teresa ^{[6
,7
]}

De Angelis, Claudia ^{[3
]}

Landucci, Elisabetta ^{[3
]}

Diodati, Lucrezia ^{[3
]}

Iezzi, Laura ^{[5
]}

Mentuccia, Lucia ^{[6
]}

Fabbri, Agnese ^{[8
]}

Barba, Maddalena ^{[1
]}

Sanguineti, Giuseppe ^{[9
]}

Marchetti, Paolo ^{[4
,10
]}

Tomao, Silverio ^{[11
]}

Mariani, Luciano ^{[12
]}

Paris, Ida ^{[13
]}

Lorusso, Vito ^{[14
]}

Vallarelli, Simona ^{[14
]}

Cassano, Alessandra ^{[15
]}

Airoldi, Francesca ^{[15
]}

Orlandi, Armando ^{[15
]}

Moscetti, Luca ^{[16
]}

Sergi, Domenico ^{[1
]}

Sarobba, Maria Giuseppina ^{[17
]}

Tonini, Giuseppe ^{[18
]}

Santini, Daniele ^{[18
]}

Sini, Valentina ^{[19
]}

Veltri, Enzo ^{[20
]}

Vaccaro, Angela ^{[5
]}

Ferrari, Laura ^{[5
]}

De Tursi, Michele ^{[4
]}

Tinari, Nicola ^{[4
]}

Grassadonia, Antonino ^{[4
]}

Greco, Filippo ^{[21
]}

Botticelli, Andrea ^{[2
]}

La Verde, Nicla ^{[22
]}

Zamagni, Claudio ^{[23
]}

Rubino, Daniela ^{[23
]}

Cortesi, Enrico ^{[24
]}

Magri, Valentina ^{[24
]}

Pomati, Giulia ^{[24
]}

Scagnoli, Simone ^{[24
]}

Capomolla, Elisabetta ^{[25
]}

Kayal, Ramy ^{[26
]}

Scinto, Angelo Fedele ^{[27
]}

Corsi, Domenico ^{[27
]}

Cazzaniga, Marina ^{[28
]}

Laudadio, Lucio ^{[29
]}

机构：

[1] IRCCS Regina Elena Natl Canc Inst, Div Med Oncol 2, Via Elio Chianesi 53, I-00144 Rome, Italy

[2] Sapienza Univ Rome, Azienda Osped St Andrea, Dept Clin & Mol Med, Rome, Italy

[3] Azienda Osped Univ Pisana, Dipartimento Oncol Dei Trapianti & Nuove Tecnol, UO Oncol Med I, Osped S Chiara, Pisa, Italy

[4] Ctr Sci Invecchiamento & Med Traslazionale CeSI M, Chieti, Italy

[5] Loc San Marciano Hosp, SS Trinita Hosp, Med Oncol Unit, Sora, Frosinone, Italy

[6] SS Trinita Hosp, Med Oncol Unit, Sora, Italy

[7] Sandro Pertini Hosp, Med Oncol, Rome, Italy

[8] Belcolle Hosp, Med Oncol Unit, Viterbo, Italy

[9] IRCCS Regina Elena Natl Canc Inst, Rome, Italy

[10] Sapienza Univ Rome, A Oncol Div, Dept Clin & Mol Med, Rome, Italy

[11] Univ Roma La Sapienza, A Oncol Div, Dept Clin & Mol Med, Rome, Italy

[12] IRCCS Regina Elena Natl Canc Inst, Dept Gynaecol Oncol, HPV Unit, Rome, Italy

[13] Univ Cattolica Sacro Cuore, Gynecol Oncol Unit, Rome, Italy

[14] Giovanni Paolo II Hosp, IRCCS, Div Med Oncol, Bari, Italy

[15] Univ Cattolica Sacro Cuore, Dept Med Oncol, Rome, Italy

[16] Univ Hosp Modena, Dept Hematol & Oncol, Div Med Oncol, Modena, Italy

[17] Osped San Francesco, Div Med Oncol, Nuoro, Italy

[18] Univ Campus Biomed Rome, Dept Oncol, Rome, Italy

[19] Santo Spirito Hosp, Oncol Unit, ASL Roma 1, Rome, Italy

[20] Osped S Maria Goretti, Div Med Oncol, Latina, Italy

[21] ASST Fatebenefratelli Sacco Fatebenefratelli, Dept Oncol, Milan, Italy

[22] ASST Fatebenefratelli Sacco Fatebenefratelli, Dept Oncol, Milan, Italy

[23] St Orsola Marcello Malpighi Hosp, SSD Oncol Med Addarii, Bologna, Italy

[24] Univ Rome, Policlin Umberto I, Med Oncol, Rome, Italy

[25] Osped Parodi Delfino, Med Oncol, Colleferro, Italy

[26] IRCCS Regina Elena Natl Canc Inst, Dept Radiol, Rome, Italy

[27] Osped San Pietro Fatebenefratelli, Med Oncol Unit, Rome, Italy

[28] ASST Monza, Oncol Unit, Monza, Italy

[29] Osped Renzetti, Med Oncol, Lanciano, Italy

[30] Mater Salutis Hosp, ULSS21, Dept Pathol Surg & Oncol, Verona, Italy

[31] ASST Bergamo Ovest, Oncol Unit, Dept Oncol, Treviglio, Italy

[32] Regina Margherita Hosp, Med Oncol Unit, Rome, Italy

[33] Tor Vergata Univ Hosp, Tor Vergata Clin Ctr, Univ Hosp, Med Oncol Unit,Dept Syst Med, Rome, Italy

[34] Univ Palermo, Sect Med Oncol, Dept Surg Oncol & Oral Sci, Palermo, Italy

[35] Univ Aquila, S Salvatore Hosp, Med Oncol Dept, Laquila, Italy

[36] Univ Politecn Marche, Azienda Osped Univ Ospedali Riuniti Clin Oncol, Ancona, Italy

[37] Univ Cattolica Sacro Cuore, Inst Gen Pathol, Rome, Italy

[38] IRCCS Regina Elena Natl Canc Inst, Biostat Unit, Via Elio Chianesi 53, I-00144 Rome, Italy

[39] IRCCS Regina Elena Natl Canc Inst, Sci Direct, Rome, Italy

来源：

JOURNAL OF CELLULAR PHYSIOLOGY | 2019年 / 234卷 / 06期

关键词：

advanced breast cancer; hormonal therapy; endocrine resistance; palbociclib; real-world setting; 1ST-LINE TREATMENT; FULVESTRANT; COMBINATION; LETROZOLE; EFFICACY; SAFETY; MULTICENTER; ABEMACICLIB; PLACEBO; WOMEN;

D O I：

10.1002/jcp.27832

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Data from 423 human epidermal growth factor receptor 2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6-35.4) and clinical benefit was 52.7% (95% CI, 48-57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At 6 months, median progression-free survival was 12 months (95% CI, 8-16) and median overall survival was 24 months (95% CI, 17-30). More favorable outcomes were associated with palbociclib in early lines, no visceral metastases and no prior everolimus/exemestane. The main toxicity reported was neutropenia. Our results provide further support to the use of palbociclib with ET in HER2-, HR+ aBC. Differences in outcomes across patients subsets remain largely unexplained.

引用

页码：7708 / 7717

页数：10

共 50 条

[1] Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
Jiao Yang
Bing Zhao
Xiaoling Ling
Donghui Li
Jiuda Zhao
Yonggang Lv
Guangxi Wang
Xinlan Liu
Nanlin Li
Jin Yang
BMC Cancer, 23
[2] Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
Yang, Jiao
Zhao, Bing
Ling, Xiaoling
Li, Donghui
Zhao, Jiuda
Lv, Yonggang
Wang, Guangxi
Liu, Xinlan
Li, Nanlin
Yang, Jin
BMC CANCER, 2023, 23 (01)
[3] Effectiveness and Safety of Palbociclib plus Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Real-World Results
Fernandez-Cuerva, Cristina
Valencia, Juan Carlos del Rio
Tamayo Bermejo, Rocio
CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2022, 75 (01): : 26 - 33
[4] Effectiveness and Safety of Palbociclib plus Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Real-World Results
Fernandez-Cuerva, C.
Del Rio, Valencia J. C.
Bermejo, R. T.
CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2022, 75 (02): : 128 - 128
[5] Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study
Palumbo, Raffaella
Torrisi, Rosalba
Sottotetti, Federico
Presti, Daniele
Rita Gambaro, Anna
Collova, Elena
Ferzi, Antonella
Agostinetto, Elisa
Maria Teragni, Cristina
Saltalamacchia, Giuseppe
Tagliaferri, Barbara
Balletti, Emanuela
Bernardo, Antonio
Quaquarini, Erica
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[6] Abemaciclib and endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: A real-world UK multicentre experience
Battisti, Nicolo Matteo Luca
Morrison, Laura
Nash, Tamsin
Senthivel, Nishanti
Kestenbaum, Samantha
Begum, Parvin
Obeid, Mariam
Hayhurst, William
Yang, Dorothy
Gafoor, Shafiah
Brown, Caroline
Rehman, Farah
Kenny, Laura
Hatcher, Olivia
Susan, Susan
Williams, Jennet
Brown, Anna
Rozati, Hamoun
Alexandros, Alexandros
Sawyer, Elinor
Gousis, Charalampos
Karapanagiotou, Eleni
Rigg, Anna
Rapti, Kleopatra
Roylance, Rebecca
Beresford, Mark
Gee, Abigail L.
Konstantis, Apostolos
King, Judy
Nathan, Mark
Spurrell, Emma
Pearce, Mark
Bradwell, Dane
Denton, Arshi
Swain, Kate
McGrath, Sophie
Allen, Mark
Ring, Alistair
Johnston, Stephen
Raja, Fharat
CANCER RESEARCH, 2022, 82 (04)
[7] Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
Porte, Baptiste
Carton, Matthieu
Loirat, Delphine
Bidard, Francois-Clement
Haroun, Linda
Bellesoeur, Audrey
Kirova, Youlia
Cottu, Paul
CANCER RESEARCH, 2021, 81 (04)
[8] Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
Porte, B.
Carton, M.
Lerebours, F.
Brain, E.
Loirat, D.
Haroun, L.
Bellesoeur, A.
Hamba, S. Bach
Kirova, Y.
Cottu, P.
BREAST, 2020, 54 : 303 - 310
[9] A Real-world Study of Everolimus Plus Aromatase Inhibitor in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer
Ardavanis-loukeris, Gerasimos
Kokkali, Stefania
Perdikari, Konstantina
Karatrasoglou, Eleni
Talagani, Sofia
Tzovaras, Alexandros
Ardavanis, Alexandros
ANTICANCER RESEARCH, 2024, 44 (04) : 1559 - 1565
[10] Adjuvant palbociclib plus endocrine therapy for hormone receptor positive/HER2 negative breast cancer: A phase II feasibility study
Mayer, Erica L.
DeMichele, Angela M.
Guo, Hao
Miller, Kathy D.
Rugo, Hope S.
Schneider, Bryan
Waks, Adrienne G.
Come, Steven E.
Mulvey, Theresa
Bartlett, Cynthia Huang
Koehler, Maria
Barry, William
Winer, Eric P.
Burstein, Harold J.
CANCER RESEARCH, 2018, 78 (04)

← 1 2 3 4 5 →